Cookson Peirce & Co. Inc. Buys New Stake in IDEXX Laboratories, Inc. $IDXX

Cookson Peirce & Co. Inc. purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,034 shares of the company’s stock, valued at approximately $700,000.

A number of other institutional investors also recently bought and sold shares of the stock. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the second quarter worth $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories during the third quarter worth $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

IDXX stock opened at $562.16 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The business has a 50-day moving average price of $563.05 and a 200 day moving average price of $631.88. The company has a market capitalization of $44.34 billion, a P/E ratio of 41.40, a PEG ratio of 3.08 and a beta of 1.56. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.